ASCO 2025 highlighted critical advancements in precision oncology - from the clinical application of AI and ctDNA to next-generation ADCs and gene therapies. These insights shared throughout the conference have direct implications for how pharma and biotech organizations shape their diagnostic and therapeutic strategies moving forward.
Read our precision medicine experts’ key take aways from each day at ASCO below.
Day 1 highlights: Friday 30th May
Artificial Intelligence in Oncology: Promise and Progress
AI took center stage on Day 1, with sessions showcasing its transformative potential across the oncology landscape. Key discussions highlighted AI’s ability to streamline cancer care, enhance clinical decision-making, and improve research efficiency. Notable findings included AI’s superior sensitivity in immunohistochemistry (IHC) scoring—particularly in identifying HER2-low and ultra-low breast cancers—and its application in biomarker assessment such as TROP2. Presenters also explored AI’s expanding role across the drug development continuum, from discovery and trial design to diagnostics and patient care. While the promise is clear, speakers emphasized the need for robust validation and regulatory oversight.
Circulating Tumor DNA: Shaping the Future of Precision Oncology
Circulating tumor DNA (ctDNA) also emerged as a key theme, with multiple sessions exploring its clinical utility. In colorectal cancer, ctDNA demonstrated strong prognostic value and potential for guiding intervention, particularly in minimal residual disease (MRD) detection as well as enabling clinical trial enrollment and shared decision-making. However, limitations in ctDNA assays sensitivity, lack of long-term survival data and guidelines remain barriers to routine adoption. However, several prospective studies on ctDNA guided management of CRC including DYNAMIC (II & III), Circulate, Circulate US and Circulate Spain could provide supportive evidence needed.
The Developmental Therapeutic session provided the preliminary results from the MONSTAR-SCREEN-3 study introduced a promising ultra-sensitive whole-genome sequencing (WGS) assay for MRD detection across tumor types, including traditionally low-shedding cancers. Furthermore, additional insights came from the I-SPY2 endocrine optimization pilot trial, which leveraged ctDNA for treatment stratification.
Developmental Therapeutics: Innovation in Early-Phase Trials
Rapid oral abstract sessions unveiled developments in targeted therapies. Early-phase trials of HER2- and HER3-directed antibody-drug conjugates (ADCs), including novel bispecific formats, showed encouraging activity in lung and other solid tumors. Although, the disappointing news of the failure of HERTHENA-Lung02 trial of HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan was also touched upon. Promising agents targeting neuroendocrine tumor markers such as delta-like ligand 3 (DLL3) and somatostatin receptor 2 (SSTR2) were also featured, signalling new avenues for precision treatment in this tumor type.
Advancing Care in Ultra-Rare Sarcomas
A dedicated session spotlighted the unique challenges in diagnosing and treating ultra-rare sarcomas, emphasizing the "data-free zone" that limits clinical knowledge and regulatory progress. Experts underscored the critical role of preclinical modeling in uncovering disease biology and accelerating the development of novel, targeted therapies.
Read full recap and implications for pharma here: ASCO 2025 Daily Highlights: Friday 30th May - Diaceutics
Day 2 highlights: Saturday 31st May
Future of Multi-Cancer Detection (MCD) Tests in Cancer Screening
Speakers emphasized the transformative potential of multi-cancer detection (MCD) tests in revolutionizing cancer screening. These tests identify cancer-related biological signatures in blood, such as DNA fragments, methylation, RNA, or proteins, using advanced algorithms powered by machine learning or artificial intelligence to predict the tissue of origin. The critical balance between high specificity to avoid false positives and high sensitivity to detect cancers was highlighted. MCD tests represent the initial step in a comprehensive screening program, with success hinging on factors like sensitivity, timely evaluation, early-stage disease curability, and screening accessibility. The session concluded that while MCD tests could redefine the screening paradigm, it is crucial to recognize that screening is a multistep process requiring robust evidence from randomized trials to ensure safety and efficacy.
Pioneering the Future of Cancer Treatment: The Transition of Gene Therapy into Solid Tumors and Lessons from Gene Therapies Adopted in Inherited Diseases
Gene therapy for solid tumors is no longer a theoretical ambition—it is a clinical reality. With continued regulatory collaboration and stakeholder engagement, these therapies are poised to redefine standards of care and expand access for patients worldwide. Recent FDA approvals and clinical breakthroughs underscore a new era of precision medicine, where T cell therapies are delivering real-world impact.
Breakthrough Therapies, Real-World Impact:
- Afami-cel: The first FDA-approved TCR therapy targeting MAGE-A4, marks a pivotal moment in the treatment of synovial sarcoma.
- Lete-cel: Targeting NY-ESO-1, is demonstrating strong clinical potential in both synovial sarcoma and myxoid round-cell liposarcoma, reinforcing the viability of TCR therapies in solid tumors.
- Lifileucel: A TIL therapy, has gained FDA approval for metastatic melanoma, validating the clinical utility of tumor-infiltrating lymphocyte approaches.
The afternoon session on gene therapy drew lessons from gene therapy in hereditary diseases, highlighting the life-changing successes of exa-cel gene therapy in sickle cell anemia. However, it also emphasized the often-prohibitive limitations of gene therapy treatments, including very high costs, limited scalability and access (especially in patient populations who would benefit most), long manufacturing times, and severe toxicities. Promising alternatives are being developed by MD Anderson Cancer Center with the use of natural killer (NK) cell therapies, which can be developed as off-the-shelf treatments derived from donors or cell lines. This enables faster and more scalable production, with lower toxicity profiles, contributing to decreased overall treatment costs.
Evolution of Kidney Cancer Biomarkers
The evolution of biomarkers in kidney cancer over the last decade was highlighted, showcasing advancements in imaging, blood-based biomarkers for detecting minimal residual disease, and emerging gene expression signatures like single-cell sequencing and spatial biology. These tools have helped subtype clear cell renal cell carcinomas and predict treatment responses, with ongoing trials aiming to improve outcomes.
Various new biomarkers in kidney cancer were showcased, including serum KIM1, which has the potential to be a significant predictor of treatment outcomes with atezolizumab in high-risk resected renal cell carcinoma (RCC). The development of a machine learning-based model that integrates diverse biomarkers, including PD-L1 score, AI platform analysis of images, and examination of extracellular matrix (ECM) factors, was also discussed. However, several limitations were acknowledged, including the need for extensive validation and incorporation of additional features like transcriptional state and genetics. Researchers exploring the microtome of RCC showed the importance of circulating MAdCAM-1 levels as a prognostic biomarker in metastatic RCC and suggested that patients with low MAdCAM-1 levels may benefit from microbiota-centered interventions. Finally, the potential to induce significant pathologic responses in a subset of patients with high-risk RCC, leading to improved disease-free survival, was highlighted. The presence of CD8+CD39+ T-cells following neoadjuvant avelumab and axitinib may be a valuable predictive biomarker for treatment outcomes.
Read full recap and implications for pharma here: ASCO 2025 Daily Highlights: Saturday 31st May - Diaceutics
Day 3 highlights: Sunday 1st June
Plenary Session
Phase 3 ATOMIC trial evolving Colon Cancer Treatment with Atezolizumab
Results of randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
Atezolizumab, combined with mFOLFOX6 chemotherapy, is set to transform the treatment landscape for stage III colon cancer with deficient mismatch repair (dMMR).
- Patients receiving atezolizumab with mFOLFOX6 showed a significant improvement in Disease Free Survival (DFS), with a three-year DFS rate of 86.4% compared to 76.6% for the chemotherapy alone group.
- The efficacy of atezolizumab was consistent across various subgroups, highlighting the broad applicability of this approach.
- Atezolizumab combined with mFOLFOX6 was well tolerated, with manageable adverse events.
Atezolizumab with mFOLFOX6 therapy represents a new era in colon cancer therapy, offering hope for better outcomes and a brighter future for patients.
Potential as a new standard treatment in resected head and neck squamous cell carcinoma for the first time in two decades...
Results of NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
Nivolumab, combined with cisplatin-radiotherapy (CRT), is set to change the treatment landscape for resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The Phase 3 NIVOPOSTOP study has demonstrated that this combination significantly improves disease-free survival (DFS) compared to the current standard of care.
- Patients receiving nivolumab with CRT showed a significant improvement in DFS, with a three-year DFS rate of 63.1% compared to 52.5% for the CRT alone group.
- The efficacy of nivolumab was consistent across various subgroups, highlighting the broad applicability of this approach.
- Nivolumab combined with CRT was well tolerated, with fewer grade 4 adverse events compared to CRT alone.
Nivolumab represents a new era in head and neck cancer therapy, offering hope for better outcomes and a brighter future for patients.
Transforming Polycythemia Vera Treatment with Rusfertide
Results from Part 1a of VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
Polycythemia vera (PV) is a condition characterized by the overproduction of red blood cells. Rusfertide is a new, self-injected peptide that mimics hepcidin and reduces erythrocytosis. The VERIFY study is a global phase 3 trial assessing Rusfertide versus placebo (PBO) in patients with PV who require frequent phlebotomies.
Review of study concluded that Rusfertide is revolutionizing the management of polycythemia vera (PV). This innovative therapy has shown significant promise in Part 1a of the phase 3 VERIFY study, meeting its primary and all key secondary endpoints. Patients treated with Rusfertide experienced a substantial reduction in the need for phlebotomies and improved hematocrit control, along with significant improvements in fatigue and symptom scores.
As we look to the future
- Additional data from longer-term follow-up will further solidify Rusfertide's role in PV treatment.
- This groundbreaking therapy offers new hope for patients, aiming to reduce the need for cytoreduction and potentially lower the risk of progression to more severe conditions like myelofibrosis or acute myeloid leukemia.
Camizestrant represents a new era in personalized breast cancer therapy, offering hope for better outcomes
Results of Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
Camizestrant, combined with CDK4/6 inhibitors, is set to transform the treatment landscape for HR+/HER2– advanced breast cancer. The groundbreaking SERENA-6 trial has demonstrated that using ctDNA to detect ESR1 mutations and guide therapy changes can significantly improve progression-free survival (PFS) for patients.
- Patients switching to camizestrant showed a median PFS of 16.0 months, nearly doubling the 9.2 months seen with continued AI therapy.
- The PFS advantage was observed across all patient subgroups, highlighting the broad applicability of this approach.
- Camizestrant was well tolerated, with a safety profile consistent with existing treatments.
Revolutionizing Gastric Cancer Treatment with Durvalumab
Results of event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
Durvalumab combined with FLOT chemotherapy is set to transform the treatment landscape for resectable gastric and gastroesophageal junction cancer (GC/GEJC). The MATTERHORN study has demonstrated that this combination significantly improves event-free survival (EFS) compared to the current standard of care.
- Patients receiving durvalumab with FLOT showed a significant improvement in EFS, with the median EFS not yet reached, compared to 32.8 months for the placebo group.
- The 24-month EFS rate was higher for the durvalumab group, highlighting the long-term benefits of this combination.
- Durvalumab combined with FLOT was well tolerated, with similar adverse event rates to the placebo group.
Durvalumab represents a new era in gastric cancer therapy, offering hope for better outcomes and a brighter future for patients.
Considerations for treating physicians
Should we offer for all? The consensus is to offer the treatment to all patients. There is no subgroup to exclude, and it is recommended for all PD-L1 subgroups.
Will OS be positive? While the MATTERHORN study's answer is "TBD," a promising curve shape and a strong design with a p-value threshold of 0.049 at final analysis.
Read full recap and implications for pharma here: ASCO 2025 Daily Highlights: Sunday 1st June - Diaceutics
Day 4 highlights: Monday 2nd June
Revolutionizing Cancer Treatment: The Latest Breakthroughs in Antibody Drug Conjugates at ASCO
Results of Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.
(Abstract 105)
SEZ6 is a marker found in small cell lung cancer (SCLC) and high-grade neuroendocrine neoplasms (NENs). There is a need for new targeted therapies for NENs. ABBV-706 is an antibody-drug conjugate targeting SEZ6, being tested in a phase 1 study for patients with advanced solid tumors. Early results showed it is safe and effective in SCLC and NENs.
ABBV-706 showed promising efficacy in high-grade NENs, supporting further development in specific subtypes.
Results of Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors.
(Abstract 106)
SHR-1826 demonstrated a manageable safety profile and promising anti-cancer activity in patients with heavily pretreated advanced solid tumors, particularly MET-altered NSCLC. These results warrant further investigation in this population.
Results of phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors.
(Abstract 107)
Nectin-4 is a cell adhesion molecule that is highly expressed in a wide variety of cancers and is associated with poor prognosis. SHR-A2102 is a novel ADC consisting of a fully humanized Nectin-4–directed monoclonal antibody, bound to topoisomerase I inhibitor payload via a cleavable linker. SHR-A2102 demonstrated a manageable safety profile and promising activity across a variety of pretreated advanced solid tumors. Multiple trials are ongoing to further assess SHR-A2102 both as monotherapy and in combination therapy for solid tumors.
Transformative power in Gynecologic Oncology: The Power of Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are transforming the landscape of gynecologic oncology. With innovative targets like HER2, TROP2, FRα, TF, Nectin-4, B7H3, and B7H4, and various payloads, ADCs are delivering unprecedented objective response rates. From the FDA-approved Mirvetuximab soravtansine for ovarian cancer and Trastuzumab deruxtecan for pan-cancer, these therapies are paving the way for more personalized and effective treatments. Stay ahead in the fight against gynecologic cancers with the latest advancements in ADC technology.
Strategic Next Steps for ADC
- Integration of Advanced Testing Technologies
Leverage existing technologies such as immunohistochemistry (IHC) and next-generation sequencing (NGS) to test for new biomarkers like c-MET, SEZ6, and Nectin-4. These technologies are already well-established in clinical laboratories and can be adapted for new biomarkers. - Material Availability
Take into consideration the amount of material available in target diseases to allow biomarker testing. In highly competitive disease spaces such as NSCLC consider NGS testing which allows analysis of multiple targets at once. - Diagnostic Partner Selection:
Collaborate with diagnostic companies that have expertise in biomarker testing and can provide comprehensive solutions, including assay development, validation, and regulatory support. This partnership will facilitate the rapid adoption of new biomarkers in clinical practice. - Laboratory Impact Assessment
Consider the impact of introducing new biomarker tests on testing laboratories including availability of technology, expertise in biomarker testing/analysis, education requirements, workload, burden of assay verification. - Regulatory and Reimbursement Consideration
Engage with regulatory bodies to ensure that new biomarker tests meet the necessary standards for approval. Work with payers to secure reimbursement for these tests, making them accessible to a broader patient population. - Ongoing Research and Development
Continue research to further understand the role of these biomarkers in cancer progression and treatment response. Invest in clinical trials to generate robust data supporting the efficacy and safety of targeted therapies based on these biomarkers.
By following these strategic steps, the pharmaceutical industry can effectively introduce new biomarkers in cancer, enhancing personalized treatment approaches and improving patient outcomes.
Contact us
If you missed us at ASCO, and would like to discuss how we can support your commercialization strategy, contact us here: Contact Us - Diaceutics
